The U.S. National Institutes of Health’s $1 billion RECOVER Initiative has picked Pfizer Inc.’s antiviral drug Paxlovid as the first treatment it will study in patients with long COVID, organizers of the study said on Thursday.
https://www.pharmalive.com/wp-content/uploads/2022/10/ReutersPaxlovid10-27-2022.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-10-27 18:41:542022-10-28 10:39:36U.S. government to test Pfizer’s Paxlovid for long COVID
